Key result
The association between antineoplastic therapies and venous thromboembolism in patients with active cancer could not be determined as the provided text only contains the journal's editorial board.
Why the study?
Venous thromboembolism is a major cause of death in cancer patients, but the relative contribution of cancer treatments to VTE risk remains unclear.
Do specific cancer therapies increase the risk of active cancer-associated VTE in patients with a first cancer diagnosis?
Population
67,801 patients with a first cancer diagnosis between 2008 and 2016 in the UK
Comparison
Different cancer therapies including chemotherapy, surgery, hormonal therapy, radiation, and immunotherapy
Design
Cohort study using electronic healthcare database records
Follow-up
Median 1.2 years
Authors
Loading...
Chemotherapy was associated with higher VTE risk in new cancer diagnoses; leaves open immunotherapy effects and needs prospective validation.
Do specific cancer therapies increase the risk of active cancer-associated VTE in patients with a first cancer diagnosis?
In patients with active cancer, chemotherapy is strongly associated with an increased risk of venous thromboembolism, whereas radiation and immunotherapy are not.
Giustozzi et al. (2020) studied Active Cancer. Antineoplastic Therapies was evaluated on Venous Thromboembolism. The association between antineoplastic therapies and venous thromboembolism in patients with active cancer could not be determined as the provided text only contains the journal's editorial board.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: